Importer of Controlled Substances, Notice of Application, Lipomed, 23957-23958 [2013-09538]
Download as PDF
23957
Federal Register / Vol. 78, No. 78 / Tuesday, April 23, 2013 / Notices
reproduction cost) payable to the United
States Treasury.
Maureen Katz,
Assistant Section Chief, Environmental
Enforcement Section, Environment and
Natural Resources Division.
[FR Doc. 2013–09500 Filed 4–22–13; 8:45 am]
BILLING CODE 4410–15–P
DEPARTMENT OF JUSTICE
mstockstill on DSK4VPTVN1PROD with NOTICES
Notice of Lodging of Proposed
Consent Decree Under the Clean Water
Act
On April 4, 2013, the Department of
Justice lodged a proposed Consent
Decree with the United States District
Court for the District of New Hampshire
in the lawsuit entitled United States v.
Torromeo Industries, Inc., Civil Action
No. 1:10–cv–509–JL. Torromeo
Industries, Inc., is a Massachusetts
corporation with a principal place of
business at 33 Old Ferry Road,
Methuen, Massachusetts. Torromeo
operates a sand, gravel, crushed stone
mining, and redi-mix concrete operation
at 18 Dorre Road, Kingston, New
Hampshire (‘‘the Facility’’).
The United States filed the underlying
action against Torromeo Industries, Inc.,
pursuant to Sections 309(b) and (d) of
the Clean Water Act (‘‘CWA’’ or ‘‘Act’’),
33 U.S.C. 1319(b) and (d). The United
States sought civil penalties and
injunctive relief for violations of
Sections 301, 308, and 402 of the CWA,
33 U.S.C. 1311, 1318, and 1342, and
applicable implementing regulations
relating to Torromeo’s discharge of
process water and storm water to the
waters of the United States in the course
of its operations at the Kingston, NH
facility.
In the proposed Consent Decree,
Torromeo Industries, Inc., agrees to
eliminate all process water discharges
from the Facility except as specifically
authorized by a National Pollutant
Discharge Elimination System
(‘‘NPDES’’) permit.
With respect to storm water runoff,
Torromeo will complete and submit to
EPA an Initial Comprehensive Facility
Compliance Evaluation (‘‘ICFCE’’) for
each Construction Materials Facility
located in New England that it owns or
operates, or which it subsequently
acquires, which shall address all
elements specified in the Consent
Decree (‘‘CD’’). Torromeo shall also
establish a Storm Water Pollution
Protection Plan (‘‘SWPPP’’) addressing
all elements specified in the CD.
Torromeo will implement a
Supplemental Environmental Project
(‘‘SEP’’), the Castleton Function Hall
VerDate Mar<15>2010
17:51 Apr 22, 2013
Jkt 229001
Pervious Concrete Project, as specified
in the CD.
Torromeo shall pay a civil penalty in
the amount of $135,000.
The publication of this notice opens
a period for public comment on the
proposed Consent Decree. Comments
should be addressed to the Assistant
Attorney General, Environment and
Natural Resources Division, and should
refer to United States v. Torromeo
Industries, Inc., Civil Action No. 1:10–
cv–509–JL; DOJ Ref. No. 90–5–1–1–
10014. All comments must be submitted
no later than thirty (30) days after the
publication date of this notice.
Comments may be submitted either by
email or by mail:
To submit
comments:
Send them to:
By email ....
pubcommentees.enrd@usdoj.gov.
Assistant Attorney General,
U.S. DOJ—ENRD, P.O. Box
7611,
Washington,
DC
20044–7611.
By mail ......
During the public comment period,
the proposed Consent Decree may be
examined and downloaded at this
Justice Department Web site: https://
www.usdoj.gov/enrd/
Consent_Decrees.html. We will provide
a paper copy of the proposed Consent
Decree upon written request and
payment of reproduction costs. Please
mail your request and payment to:
Consent Decree Library, U.S. DOJ—
ENRD, P.O. Box 7611, Washington, DC
20044–7611.
Please enclose a check or money order
for $15.00 (25 cents per page
reproduction cost) payable to the United
States Treasury.
Maureen M. Katz,
Assistant Section Chief, Environmental
Enforcement Section, Environment and
Natural Resources Division.
[FR Doc. 2013–09521 Filed 4–22–13; 8:45 am]
BILLING CODE 4410–CW–P
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
Importer of Controlled Substances,
Notice of Application, Lipomed
Pursuant to Title 21 Code of Federal
Regulations 1301.34 (a), this is notice
that on January 29, 2013, Lipomed, One
Broadway, Cambridge, Massachusetts
02142, made application by letter to the
Drug Enforcement Administration
(DEA) for registration as an importer of
PO 00000
Frm 00075
Fmt 4703
Sfmt 4703
the following basic classes of controlled
substances:
Drug
JWH–250 (6250) ..........................
SR–18 also known as RCS–8
(7008).
JWH–019 (7019) ..........................
JWH–081 (7081) ..........................
SR–19 also known as RCS–4
(7104).
JWH–122 (7122) ..........................
AM–2201 (7201) ...........................
JWH–203 (7203) ..........................
2C–T–2 (7385) .............................
JWH–398 (7398) ..........................
2C–D (7508) .................................
2C–E (7509) .................................
2C–H (7517) .................................
2C–I (7518) ..................................
2C–C (7519) .................................
2C–N (7521) .................................
2C–P (7524) .................................
2C–T–4 (7532) .............................
AM–694 (7694) .............................
Schedule
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
The company plans to import
analytical reference standards for
distribution to its customers for research
and analytical purposes.
Any bulk manufacturer who is
presently, or is applying to be,
registered with DEA to manufacture
such basic classes of controlled
substances listed in schedule I, which
fall under the authority of section
1002(a)(2)(B) of the Act 21 U.S.C.
952(a)(2)(B) may, in the circumstances
set forth in 21 U.S.C. 958(i), file
comments or objections to the issuance
of the proposed registration and may, at
the same time, file a written request for
a hearing on such application pursuant
to 21 CFR § 1301.43, and in such form
as prescribed by 21 CFR § 1316.47.
Any such written comments or
objections should be addressed, in
quintuplicate, to the Drug Enforcement
Administration, Office of Diversion
Control, Federal Register Representative
(ODL), 8701 Morrissette Drive,
Springfield, Virginia 22152; and must be
filed no later than May 23, 2013.
This procedure is to be conducted
simultaneously with, and independent
of, the procedures described in 21 CFR
§ 1301.34(b), (c), (d), (e), and (f). As
noted in a previous notice published in
the Federal Register on September 23,
1975, 40 FR 43745–46, all applicants for
registration to import a basic class of
any controlled substance in schedules I
or II are, and will continue to be,
required to demonstrate to the Deputy
Assistant Administrator, Office of
Diversion Control, Drug Enforcement
Administration, that the requirements
for such registration pursuant to 21
U.S.C. 958(a); 21 U.S.C. 823(a); and 21
E:\FR\FM\23APN1.SGM
23APN1
23958
Federal Register / Vol. 78, No. 78 / Tuesday, April 23, 2013 / Notices
CFR § 1301.34(b), (c), (d), (e), and (f) are
satisfied.
DEPARTMENT OF JUSTICE
Dated: April 16, 2013.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of
Diversion Control, Drug Enforcement
Administration.
Manufacturer of Controlled
Substances; Notice of Application;
Research Triangle Institute
[FR Doc. 2013–09538 Filed 4–22–13; 8:45 am]
BILLING CODE 4410–09–P
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
mstockstill on DSK4VPTVN1PROD with NOTICES
Importer of Controlled Substances:
Notice of Registration; Fisher Clinical
Services, Inc.
By Notice dated November 27, 2012,
and published in the Federal Register
on December 5, 2012, 77 FR 72409,
Fisher Clinical Services, Inc., 7554
Schantz Road, Allentown, Pennsylvania
18106, made application to the Drug
Enforcement Administration (DEA) to
be registered as an importer of
Levorphanol (9220), a basic class of
controlled substance in schedule II.
The company plans to import the
listed substances for analytical research
and clinical trials.
No comments or objections have been
received. DEA has considered the
factors in 21 U.S.C. 823(a) and § 952(a),
and determined that the registration of
Fisher Clinical Services, Inc., to import
the basic class of controlled substance is
consistent with the public interest and
with United States obligations under
international treaties, conventions, or
protocols in effect on May 1, 1971. DEA
has investigated Fisher Clinical
Services, Inc., to ensure that the
company’s registration is consistent
with the public interest. The
investigation has included inspection
and testing of the company’s physical
security systems; verification of the
company’s compliance with state and
local laws; and a review of the
company’s background and history.
Therefore, pursuant to 21 U.S.C.
952(a) and § 958(a), and in accordance
with 21 CFR 1301.34, the above named
company is granted registration as an
importer of the basic class of controlled
substance listed.
Dated: April 16, 2013.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of
Diversion Control, Drug Enforcement
Administration.
[FR Doc. 2013–09537 Filed 4–22–13; 8:45 am]
BILLING CODE 4410–09–P
VerDate Mar<15>2010
17:51 Apr 22, 2013
Jkt 229001
Drug Enforcement Administration
Pursuant to § 1301.33(a), Title 21 of
the Code of Federal Regulations (CFR),
this is notice that on March 26, 2013,
Research Triangle Institute, Poonam G.
Pande, Ph.D., RPH, RAC, Hermann
Building, East Institute Drive, P.O. Box
12194, Research Triangle Park, North
Carolina 27709, made application by
renewal to the Drug Enforcement
Administration (DEA) to be registered as
a bulk manufacturer of the following
basic classes of controlled substances:
Drug
Schedule
Marihuana (7360) .........................
Cocaine (9041) .............................
I
II
The Institute will manufacture
marihuana, and cocaine derivatives for
use by their customers in analytical kits,
reagents, and reference standards as
directed by the National Institute on
Drug Abuse.
Any other such applicant, and any
person who is presently registered with
DEA to manufacture such substances,
may file comments or objections to the
issuance of the proposed registration
pursuant to 21 CFR 1301.33(a).
Any such written comments or
objections should be addressed, in
quintuplicate, to the Drug Enforcement
Administration, Office of Diversion
Control, Federal Register Representative
(ODL), 8701 Morrissette Drive,
Springfield, Virginia 22152; and must be
filed no later than June 24, 2013.
Dated: April 16, 2013.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of
Diversion Control, Drug Enforcement
Administration.
(DEA) to be registered as a bulk
manufacturer of Carfentanil (9743), a
basic class of controlled substance listed
in schedule II.
The company plans to manufacture
the above listed controlled substance for
sale to veterinary pharmacies, zoos, and
for other animal and wildlife
applications.
Any other such applicant, and any
person who is presently registered with
DEA to manufacture such substance,
may file comments or objections to the
issuance of the proposed registration
pursuant to 21 CFR 1301.33(a).
Any such written comments or
objections should be addressed, in
quintuplicate, to the Drug Enforcement
Administration, Office of Diversion
Control, Federal Register Representative
(ODL), 8701 Morrissette Drive,
Springfield, Virginia 22152; and must be
filed no later than June 24, 2013.
Dated: April 16, 2013.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of
Diversion Control, Drug Enforcement
Administration.
[FR Doc. 2013–09535 Filed 4–22–13; 8:45 am]
BILLING CODE 4410–09–P
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
Manufacturer of Controlled
Substances; Notice of Registration;
S & B Pharma Inc.
By Notice dated May 31, 2012, and
published in the Federal Register on
June 8, 2012, 77 FR 34073, S & B
Pharma Inc., 405 South Motor Avenue,
Azusa, California 91702–3232, made
application to the Drug Enforcement
Administration (DEA) to be registered as
a bulk manufacturer of the following
basic classes of controlled substances:
Drug
Schedule
[FR Doc. 2013–09533 Filed 4–22–13; 8:45 am]
BILLING CODE 4410–09–P
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
Manufacturer of Controlled
Substances; Notice of Application;
Wildlife Laboratories, Inc.
Pursuant to § 1301.33(a), Title 21 of
the Code of Federal Regulations (CFR),
this is notice that on March 7, 2013,
Wildlife Laboratories Inc., 1230 W. Ash
Street, Suite D, Windsor, Colorado
80550, made application by renewal to
the Drug Enforcement Administration
PO 00000
Frm 00076
Fmt 4703
Sfmt 4703
Gamma
Hydroxybutyric
Acid
(2010).
Tetrahydrocannabinols (7370) .....
Methamphetamine (1105) ............
Pentobarbital (2270) .....................
Nabilone (7379) ............................
I
I
II
II
II
The company plans to manufacture
bulk controlled substances for use in
product development and for
distribution to its customers.
No comments or objections have been
received. DEA has considered the
factors in 21 U.S.C. 823(a), and
determined that the registration of
S & B Pharma Inc., to manufacture the
listed basic classes of controlled
substances is consistent with the public
E:\FR\FM\23APN1.SGM
23APN1
Agencies
[Federal Register Volume 78, Number 78 (Tuesday, April 23, 2013)]
[Notices]
[Pages 23957-23958]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: 2013-09538]
-----------------------------------------------------------------------
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
Importer of Controlled Substances, Notice of Application, Lipomed
Pursuant to Title 21 Code of Federal Regulations 1301.34 (a), this
is notice that on January 29, 2013, Lipomed, One Broadway, Cambridge,
Massachusetts 02142, made application by letter to the Drug Enforcement
Administration (DEA) for registration as an importer of the following
basic classes of controlled substances:
------------------------------------------------------------------------
Drug Schedule
------------------------------------------------------------------------
JWH-250 (6250)............................. I
SR-18 also known as RCS-8 (7008)........... I
JWH-019 (7019)............................. I
JWH-081 (7081)............................. I
SR-19 also known as RCS-4 (7104)........... I
JWH-122 (7122)............................. I
AM-2201 (7201)............................. I
JWH-203 (7203)............................. I
2C-T-2 (7385).............................. I
JWH-398 (7398)............................. I
2C-D (7508)................................ I
2C-E (7509)................................ I
2C-H (7517)................................ I
2C-I (7518)................................ I
2C-C (7519)................................ I
2C-N (7521)................................ I
2C-P (7524)................................ I
2C-T-4 (7532).............................. I
AM-694 (7694).............................. I
------------------------------------------------------------------------
The company plans to import analytical reference standards for
distribution to its customers for research and analytical purposes.
Any bulk manufacturer who is presently, or is applying to be,
registered with DEA to manufacture such basic classes of controlled
substances listed in schedule I, which fall under the authority of
section 1002(a)(2)(B) of the Act 21 U.S.C. 952(a)(2)(B) may, in the
circumstances set forth in 21 U.S.C. 958(i), file comments or
objections to the issuance of the proposed registration and may, at the
same time, file a written request for a hearing on such application
pursuant to 21 CFR Sec. 1301.43, and in such form as prescribed by 21
CFR Sec. 1316.47.
Any such written comments or objections should be addressed, in
quintuplicate, to the Drug Enforcement Administration, Office of
Diversion Control, Federal Register Representative (ODL), 8701
Morrissette Drive, Springfield, Virginia 22152; and must be filed no
later than May 23, 2013.
This procedure is to be conducted simultaneously with, and
independent of, the procedures described in 21 CFR Sec. 1301.34(b),
(c), (d), (e), and (f). As noted in a previous notice published in the
Federal Register on September 23, 1975, 40 FR 43745-46, all applicants
for registration to import a basic class of any controlled substance in
schedules I or II are, and will continue to be, required to demonstrate
to the Deputy Assistant Administrator, Office of Diversion Control,
Drug Enforcement Administration, that the requirements for such
registration pursuant to 21 U.S.C. 958(a); 21 U.S.C. 823(a); and 21
[[Page 23958]]
CFR Sec. 1301.34(b), (c), (d), (e), and (f) are satisfied.
Dated: April 16, 2013.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of Diversion Control, Drug
Enforcement Administration.
[FR Doc. 2013-09538 Filed 4-22-13; 8:45 am]
BILLING CODE 4410-09-P